Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
KEYTRUDA pembrolizumab (rch) 100mg/4 mL concentrated injection vial Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA pembrolizumab (rch) 100mg/4 mL concentrated injection vial
Accepted date
Jul-2024
Active ingredients
pembrolizumab
Proposed indication
For the treatment of unresectable advanced or metastatic malignant pleural mesothelioma.
Application type
C (new indication)
Publication date
Jul-2024